Skip to content
Open·Listed in the source's current feed today

INCLUDE Project: Clinical Trials Phased Awards for Down syndrome Research (R61/R33 Clinical Trial Required)

National Institutes of Health

Apply at National Institutes of Health

Free. Verify your email, then we send one reminder only.

Posted
Oct 23, 2025
Amount
Program total $3M
Closes
Jun 15, 2028 (in 642 days)

See more open grant funding like this

Get alerted when new grant funding like this opens.

Checking your account…

Free. Everyone sees new listings after 10 days. Unsubscribe anytime.

Classification and identifiers

Solicitation number
RFA-OD-27-005
Assistance listing (CFDA)
93.395

Amount

Program total $3M

Who can apply

NonprofitsFor-profitsSmall businessSchool districtsNonprofits (non-501c3)Housing authorities

Nonprofits, including small and volunteer-run organizations and Small businesses can all apply here. Check the eligibility details below to see if your organization fits.

Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

About this opportunity

The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome. The purpose of this Notice of Funding Opportunity (NOFO) encourages Exploratory/Developmental Phased Innovation (R61/R33) grant applications to support development of clinical trials to treat critical and co-occurring health conditions in individuals with Down syndrome. The proposed research aims should be milestone-driven. The total project period for an application submitted in response to this NOFO may not exceed five years. This NOFO provides support for up to two years (R61 phase) for preliminary/developmental/planning studies, followed by possible transition to clinical trial support (R33) of...

Refine this search